QURE Stock Risk & Deep Value Analysis
Uniqure NV
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About QURE Stock
We analyzed Uniqure NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran QURE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is QURE Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for QURE?
- ⚠
Negative or inconclusive clinical data from AMT-130 Phase 1/2 trials (safety or efficacy)
- ⚠
Slower than expected Hemgenix revenue ramp-up or reduced milestone payments
- ⚠
Increased cash burn without successful financing or offsetting revenue
- ⚠
Emergence of superior competitive treatments for Huntington's disease
- ⚠
Regulatory setbacks or unexpected delays in clinical development
Unlock QURE Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Uniqure NV (QURE) Do?
Market Cap
$4.24B
Sector
Healthcare
Industry
Biotechnology
Employees
209
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Visit Uniqure NV WebsiteIs QURE Stock Undervalued?
Unlock the full AI analysis for QURE
Get the complete DVR score, risk analysis, and more
Does QURE Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable for 10-20 years due to the high scientific, regulatory, and financial barriers to entry in gene therapy, especially for CNS disorders. Proprietary AAV vector and manufacturing expertise provide a significant head start.
Moat Erosion Risks
- •Clinical trial failure of AMT-130 or significant safety concerns
- •Emergence of a superior gene therapy platform or alternative treatment modality for HD
- •Patent challenges or expiration impacting core IP
QURE Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive QURE Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early May 2026)
- •Updates on Hemgenix commercial rollout and milestone payments from CSL Behring
- •Updates on AMT-130 patient recruitment and safety monitoring from ongoing Phase 1/2 trials
Medium-Term (6-18 months)
- •Initial or longer-term follow-up clinical data readout from higher-dose cohorts of AMT-130 Phase 1/2 trial (e.g., safety, biomarker trends, functional assessments)
- •Potential discussions with regulatory authorities (FDA/EMA) regarding pivotal trial design for AMT-130
- •Strategic partnership opportunities for other pipeline assets or platform capabilities
Long-Term (18+ months)
- •Initiation of pivotal Phase 2/3 clinical trials for AMT-130
- •Breakthrough Therapy Designation or similar for AMT-130 based on strong efficacy data
- •Global regulatory submissions and approvals for AMT-130 in Huntington's disease
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for QURE?
- ✓
Positive or encouraging clinical data from AMT-130 Phase 1/2 trials (especially from higher dose cohorts)
- ✓
Accelerating Hemgenix sales and milestone payments from CSL Behring
- ✓
Extension of cash runway through prudent financial management or non-dilutive financing
- ✓
Strategic partnerships for other pipeline assets or platform expansion
Bull Case Analysis
See what could go right with Premium
Compare QURE to Similar Stocks
See how Uniqure NV stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for QURE (Uniqure NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
